Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2AMGN : Amgen's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...
What is William Blair’s Forecast for Amgen Q4 Earnings?
Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...
Amgen: Riding The MariTide Of Monthly Weight Loss
MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...
Investor's Business Daily on MSN5d
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.
How a skin drug trial could help Peninsula biotech pull off key merger
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Fierce Pharma5d
Trial results enhance Bristol Myers' bid for Sotyktu in psoriatic arthritis
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
Amgen And Kyowa Kirin Provide Top-line Results From Rocatinlimab Phase 3 Ignite Study In Adults With Moderate To Severe Atopic Dermatitis
Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...